Table 2 Factors associated with CIP severity.
Grade 2 (N = 14) | Grade ≧3 (N = 7) | P | |
|---|---|---|---|
Age (years), median (IQR) | 60 (56.75–66.25) | 65(54–72) | 0.369 |
Smoking status | |||
Never (N = 6) | 5 (35.7%) | 1(14.3%) | 0.614 |
Thoracic radiotherapy (N = 9) | 6 (42.9%) | 3 (42.9%) | 0.676 |
Pre-ILD | |||
Yes (N = 6) | 1(7.1%) | 5(71.4)% | 0.006 |
PD1inhibitor (N = 16) | 11(78.6%) | 5 (71.4%) | 0.557 |
Duration of immunotherapy | |||
< 3 months (N = 12) | 6 (42.9%) | 6 (85.7%) | 0.078 |
LDH, median (IU/L) (IQR) | 202.5 (171.25–236.35) | 240.0 (162.0–364.0) | 0.191 |
hsCRP, median (mg/L) (IQR) | 23.9 (8.46–81.5) | 51.0 (33.44–78.53) | 0.452 |
Blood routine test | |||
Lymphocyte, median (K/mcL) (IQR) | 0.98 (0.74–1.50) | 0.60 (0.60–1.0)) | 0.167 |
Eosinophil, median (K/mcL) (IQR) | 0.1 (0.0–1.480) | 0.5 (0.1–2.3)) | 0.246 |
Neutrophil, median (K/mcL) (IQR) | 3.67 (2.33–4.08) | 4.7 (3.2–7.7) | 0.218 |
NLR, median (IQR) | 3.57 (2.30–5.77)) | 6.33 (5.35–9.63) | 0.025 |
BALF | |||
Lymphocyte percentage, median (IQR) | 21.50 (11.75–29.75) | 56.0 (25.5–64.0)) | 0.032 |
CD4/CD8 ≧1 (%) (N = 15) | 3 (30%) | 3(60%) | 0.329 |
Pathology (N = 13) | |||
OP (N = 5) | 3 | 2 | |
AFOP (N = 3) | 2 | 1 | |
NSIP (N = 3) | 3 | 0 | |
DAD (N = 2) | 2 | 0 | |
Survival rate (N = 15) (%) | 11(78.6%) | 4(57.1%) | 0.299 |
